Proliferative glomerulonephritis with monoclonal IgG deposits in an adolescent successfully treated with daratumumab

Svabova, Eva; Zieg, Jakub; Sukova, Martina; Flachsova, Eva; Kment, Martin; Tesar, Vladimir

doi:10.1007/s00467-024-06425-2

Proliferative glomerulonephritis with monoclonal IgG deposits in an adolescent successfully treated with daratumumab

Document detail

ID

doi:10.1007/s00467-024-06425-2...

Author

Svabova, Eva Zieg, Jakub Sukova, Martina Flachsova, Eva Kment, Martin Tesar, Vladimir

Langue

Editor

Springer

Year

2024

listing date

6/12/2024

Keywords

adolescent daratumumab proliferative glomerulonephritis w... proteinuria deposits daratumumab

Metrics

Abstract

There is no specific treatment for proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID), a disease that is very rare in the pediatric population.

We report the case of a 15-year-old boy who presented with mildly reduced kidney function and nephrotic syndrome.

Kidney biopsy revealed PGNMID with monoclonal deposits of IgG3 with kappa light chain restriction.

Flow cytometry showed a significant CD38 plasma cell population in the peripheral blood in the absence of other signs of hematological malignancy.

The patient was treated with a 6-month course of daratumumab, a monoclonal antibody targeting CD38.

There was a significant reduction in proteinuria and normalization of kidney function.

Based on positive experience with adults, daratumumab should also be studied in children with PGNMID.

Svabova, Eva,Zieg, Jakub,Sukova, Martina,Flachsova, Eva,Kment, Martin,Tesar, Vladimir, 2024, Proliferative glomerulonephritis with monoclonal IgG deposits in an adolescent successfully treated with daratumumab, Springer